| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5927354 | American Heart Journal | 2012 | 10 Pages |
Abstract
Dalcetrapib up to 600 mg, combined with pravastatin, increased HDL-C and altered lipoprotein profile, HDL composition, and HDL function, with little further change at a 900-mg dose. The impact on cardiovascular events in dyslipidemic patients is being evaluated.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Christie M. MD, Michael MD, Eric J. PhD, Tracy MSc, David MBBS, Evan A. MD, PhD,